PMID- 23052187
OWN - NLM
STAT- MEDLINE
DCOM- 20130509
LR  - 20201209
IS  - 1421-9794 (Electronic)
IS  - 0009-3157 (Linking)
VI  - 58
IP  - 4
DP  - 2012
TI  - Therapy of 1,025 severely ill patients with complicated infections in a German 
      multicenter study: safety profile and efficacy of tigecycline in different 
      treatment modalities.
PG  - 282-94
LID - 10.1159/000342451 [doi]
AB  - This large prospective non-interventional study investigated the effects of 
      tigecycline either as single agent or in combination with other antimicrobial 
      agents in 1,025 patients treated in clinical routine at German hospitals. 
      Sixty-five percent of the patients had APACHE II scores > 15, indicating high 
      overall disease severity. Complicated intra-abdominal infections (cIAI) or 
      complicated skin and skin tissue infections (cSSTI) were the most common 
      indications, with Staphylococcus aureus, Enterococcus faecium and Escherichia 
      coli being the most frequently isolated pathogens. Clinical success was reported 
      at the end of tigecycline therapy in 74.2% of the total population, in 75.4% of 
      the cIAI and in 82.2% of the cSSTI patients. The subpopulation (28.0% of the 
      patients) infected with multidrug-resistant pathogens (methicillin-resistant S. 
      aureus, extended-spectrum beta-lactamase producers and vancomycin-resistant 
      enterococci) were treated with similar success rates as the overall population. 
      Tigecycline was generally well tolerated. Drug-related adverse events (AEs) were 
      reported in 7.7% of the total population; 2.5% had serious AEs mostly 
      attributable to inefficacy of therapy or deterioration of the disease. Mortality 
      rates were consistent with the types of infection and severity of illness. There 
      was no indication of excessive mortality associated with tigecycline as had been 
      suggested in previously performed meta-analyses. In this large non-interventional 
      study performed in the clinical routine setting, tigecycline achieved favorable 
      clinical success rates in a patient population with high severity of illness and 
      a high prevalence of multidrug-resistant pathogens and showed a good safety and 
      tolerability profile.
CI  - Copyright (c) 2012 S. Karger AG, Basel.
FAU - Bodmann, Klaus-Friedrich
AU  - Bodmann KF
AD  - Klinik fur Internistische Intensivmedizin und Interdisziplinare Notfallaufnahme, 
      Werner Forssmann Hospital, Klinikum Barnim GmbH, Eberswalde, Germany.
FAU - Heizmann, Wolfgang R
AU  - Heizmann WR
FAU - von Eiff, Christof
AU  - von Eiff C
FAU - Petrik, Christian
AU  - Petrik C
FAU - Loschmann, Peter-Andreas
AU  - Loschmann PA
FAU - Eckmann, Christian
AU  - Eckmann C
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20121004
PL  - Switzerland
TA  - Chemotherapy
JT  - Chemotherapy
JID - 0144731
RN  - 0 (Anti-Bacterial Agents)
RN  - 70JE2N95KR (Tigecycline)
RN  - FYY3R43WGO (Minocycline)
SB  - IM
MH  - APACHE
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Bacterial Agents/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Enterococcus/isolation & purification
MH  - Escherichia coli/isolation & purification
MH  - Female
MH  - Germany
MH  - Humans
MH  - Intensive Care Units
MH  - Intraabdominal Infections/complications/*drug therapy/microbiology
MH  - Logistic Models
MH  - Male
MH  - Methicillin-Resistant Staphylococcus aureus/isolation & purification
MH  - Middle Aged
MH  - Minocycline/adverse effects/*analogs & derivatives/therapeutic use
MH  - Multiple Organ Failure/etiology
MH  - Prospective Studies
MH  - Sepsis/etiology
MH  - Severity of Illness Index
MH  - Skin Diseases, Bacterial/complications/*drug therapy/microbiology
MH  - Staphylococcus aureus/isolation & purification
MH  - Tigecycline
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2012/10/12 06:00
MHDA- 2013/05/10 06:00
CRDT- 2012/10/12 06:00
PHST- 2012/01/17 00:00 [received]
PHST- 2012/08/07 00:00 [accepted]
PHST- 2012/10/12 06:00 [entrez]
PHST- 2012/10/12 06:00 [pubmed]
PHST- 2013/05/10 06:00 [medline]
AID - 000342451 [pii]
AID - 10.1159/000342451 [doi]
PST - ppublish
SO  - Chemotherapy. 2012;58(4):282-94. doi: 10.1159/000342451. Epub 2012 Oct 4.